Bristol Myers Squibb Company $BMY Holdings Lifted by Mn Services Vermogensbeheer B.V.

Mn Services Vermogensbeheer B.V. boosted its position in Bristol Myers Squibb Company (NYSE:BMY) by 4.7% in the third quarter, according to its most recent filing with the SEC. The institutional investor owned 622,760 shares of the biopharmaceutical company’s stock after purchasing an additional 27,824 shares during the period. Mn Services Vermogensbeheer B.V.’s holdings in Bristol Myers Squibb were worth $38,860,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Diversified Management Inc. bought a new position in shares of Bristol Myers Squibb during the 3rd quarter worth approximately $288,000. Allen Mooney & Barnes Investment Advisors LLC increased its position in shares of Bristol Myers Squibb by 6.5% during the third quarter. Allen Mooney & Barnes Investment Advisors LLC now owns 35,184 shares of the biopharmaceutical company’s stock valued at $2,195,000 after acquiring an additional 2,133 shares during the last quarter. Grove Bank & Trust increased its position in shares of Bristol Myers Squibb by 2.7% during the third quarter. Grove Bank & Trust now owns 23,039 shares of the biopharmaceutical company’s stock valued at $1,438,000 after acquiring an additional 605 shares during the last quarter. Farther Finance Advisors LLC lifted its holdings in Bristol Myers Squibb by 28.5% during the third quarter. Farther Finance Advisors LLC now owns 190,235 shares of the biopharmaceutical company’s stock worth $12,093,000 after acquiring an additional 42,218 shares during the period. Finally, Apella Capital LLC boosted its position in Bristol Myers Squibb by 159.2% in the third quarter. Apella Capital LLC now owns 33,162 shares of the biopharmaceutical company’s stock worth $2,069,000 after purchasing an additional 20,370 shares during the last quarter. Hedge funds and other institutional investors own 76.41% of the company’s stock.

Bristol Myers Squibb Trading Down 0.3%

Shares of BMY opened at $59.51 on Friday. Bristol Myers Squibb Company has a fifty-two week low of $42.52 and a fifty-two week high of $68.64. The business has a 50-day moving average of $64.27 and a 200 day moving average of $60.28. The firm has a market cap of $121.57 billion, a P/E ratio of 13.11, a price-to-earnings-growth ratio of 0.28 and a beta of 0.19. The company has a debt-to-equity ratio of 1.89, a quick ratio of 1.38 and a current ratio of 1.53.

Bristol Myers Squibb (NYSE:BMY) last issued its earnings results on Thursday, July 30th. The biopharmaceutical company reported $2.04 earnings per share for the quarter, topping analysts’ consensus estimates of $1.60 by $0.44. The firm had revenue of $12.97 billion during the quarter, compared to analyst estimates of $11.74 billion. Bristol Myers Squibb had a net margin of 18.87% and a return on equity of 66.90%. The company’s quarterly revenue was up 5.7% on a year-over-year basis. During the same quarter last year, the business earned $1.46 earnings per share. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. As a group, research analysts forecast that Bristol Myers Squibb Company will post 6.95 EPS for the current year.

Bristol Myers Squibb Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, November 2nd. Shareholders of record on Friday, October 2nd will be issued a dividend of $0.63 per share. The ex-dividend date of this dividend is Friday, October 2nd. This represents a $2.52 dividend on an annualized basis and a yield of 4.2%. Bristol Myers Squibb’s payout ratio is presently 55.51%.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on BMY shares. Zacks Research raised Bristol Myers Squibb from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, September 23rd. Truist Financial restated a “buy” rating and set a $70.00 price target (up from $65.00) on shares of Bristol Myers Squibb in a research report on Friday, July 31st. HSBC restated a “hold” rating and set a $65.00 price objective (up from $60.00) on shares of Bristol Myers Squibb in a report on Thursday, September 10th. Piper Sandler reiterated an “overweight” rating and issued a $82.00 target price (up from $75.00) on shares of Bristol Myers Squibb in a research note on Wednesday, September 16th. Finally, Argus raised shares of Bristol Myers Squibb from a “hold” rating to a “buy” rating and set a $75.00 target price for the company in a research report on Wednesday, August 5th. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, eleven have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $66.72.

Insider Transactions at Bristol Myers Squibb

In other Bristol Myers Squibb news, SVP Phil M. Holzer sold 500 shares of the stock in a transaction on Tuesday, August 25th. The stock was sold at an average price of $67.50, for a total transaction of $33,750.00. Following the sale, the senior vice president owned 16,862 shares in the company, valued at $1,138,185. This represents a 2.88% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 0.05% of the stock is owned by insiders.

More Bristol Myers Squibb News

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: ZENBEXUS delivered a significant Phase 3 result. Bristol Myers said the iberdomide combination with daratumumab and dexamethasone produced superior progression-free survival versus standard of care in relapsed or refractory multiple myeloma, cutting the risk of disease progression or death by 51%. The result strengthens the company’s pipeline and could support broader use of the therapy. Bristol Myers Squibb Announces ZENBEXUS Phase 3 Results
• Positive Sentiment: ZENBEXUS met the primary progression-free-survival endpoint in a pivotal trial. The update adds evidence behind the drug’s commercial potential following an earlier approval tied to achievement of another endpoint in the same study. BMS Zenbexus Meets PFS Endpoint
• Positive Sentiment: Analysts expect another earnings beat. Coverage points to Bristol Myers’ history of exceeding estimates and a favorable combination of earnings expectations and estimate revisions, though this is a forecast rather than a reported result. Will Bristol Myers Beat Estimates Again
• Positive Sentiment: Growth assets and income appeal remain part of the bullish case. Coverage highlights Reblozyl’s sales growth and potential new indications, a Camzyos label expansion, and BMY’s relatively attractive value and dividend profile as offsets to declining legacy-drug sales.
• Neutral Sentiment: ZENBEXUS’ ultimate impact will depend on regulatory steps, commercial uptake and competitive positioning in multiple myeloma.
• Negative Sentiment: Cantor Fitzgerald lowered its BMY price target from $59 to $53 and maintained a Neutral rating. The reduced target signals limited near-term upside in the firm’s view and is the clearest negative analyst catalyst in the latest coverage.

Bristol Myers Squibb Profile

Bristol Myers Squibb (NYSE:BMY) is a global biopharmaceutical company that discovers, develops and commercializes prescription medicines. Its research and commercial activities focus primarily on oncology, hematology, immunology, cardiovascular disease and neuroscience. The company serves patients and healthcare providers in the United States and international markets.

Bristol Myers Squibb’s portfolio includes medicines such as Opdivo and Yervoy for certain cancers, Eliquis for the prevention of blood clots and stroke, Revlimid and Pomalyst for blood cancers, and Abraxane for certain solid tumors.